1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6DDEFFDA6C54714EA8525759A0072232E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/effective-brand-team-management-critical-success-factors?opendocument
18
19opendocument
2018.97.14.86
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Brand+Management+and+Product+Leadership

Effective Brand Team Management: Critical Success Factors

ID: 5039


Features:

2 Info Graphics

7 Data Graphics

35 Metrics

11 Best Practices


Pages/Slides: 20


Published: Pre-2020


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Effective Brand Team Management: Critical Success Factors"


STUDY OVERVIEW
Revenue in biotechnology and pharmaceutical companies is driven by product sales. Since the drugs being sold on the market are the most significant assets these companies own and operate, it is only logical that the way brands are managed should be assessed for risk and evaluated in terms of their governance principles. This study examines how brand teams manage their stakeholder relationships and decision rights, including: meeting frequencies, performance-based compensation and reviews and brand performance measures. Executives and managers working with brand teams can use this research to compare their teams' critical work practices and management performance practices with those outlined in this study.

Key Topics

  • Executive Summary
  • Critical Work Practices
  • Team Behaviors
  • Managing Performance

Key Metrics
  • Frequency of a standing meeting agenda for brand team
  • Frequency of meetings for core team
  • Communication of Brand Team decisions to extended team and organization
  • Average product growth rates by brand team compensation structure
  • Top three performance metrics to monitor brand performance
  • Brand team incentives based on performance of brand
  • Brand team role in performance evaluations of core and extended team members

Key Findings
  • Brand growth shows no correlation to performance-based compensation.
  • When there are procedural oversights by management, there can be drastic implications on profit margins.

Methodology

This research is based on benchmark survey data from 33 participants from 26 pharmaceutical and biotechnology companies. Interviews were conducted with 10 senior leaders from among the benchmark partners.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Medical Device; Biotech; Chemical; Manufacturing; Consumer Products


Companies Profiled:
Abbott; Takeda; Stiefel; Shire; Schwarz Pharmaceuticals; Roche; Purdue Pharma; Orchid; Novo Nordisk; Novartis; Merial; Johnson & Johnson; GlaxoSmithKline; Genentech; Eli Lilly; Cephalon; Inc.; Biogen Idec; Bayer; Schering AG; Amylin; Alcon Laboratories

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.